
    
      The study consisted of ascending dose groups; each dose group was investigated in a new group
      of 8 healthy male subjects (6 on active drug and 2 on placebo). In addition, the study
      included a biocomparison part (dose group 2), an absolute bioavailability part (dose group
      4), and a mass balance / metabolism part (dose group 3).
    
  